Analyst downgrades: MRK, AZN, MI, ONT and ZION
Posted Jul 7th 2008 11:44AM by Laurie Pasternack
Filed under: Analyst Reports, Analyst Upgrades and Downgrades, Merck and Co (MRK)
.gif)
MOST NOTEWORTHY: Merck, On2 Technologies and Zions Bancorp were today's noteworthy downgrades:
- UBS downgraded Merck & Co Inc (NYSE: MRK) to Neutral from Buy citing slowing Gardasil trends and vaccine supply issues.
- Merriman cut On2 Technologies Inc (AMEX: ONT) to Neutral from Buy to reflect the reduced visibility into financials and management changes.
- Baird downgraded shares of Zions Bancorporation (NASDAQ: ZION) to Neutral from Outperform to reflect deteriorating credit quality and growing capital concerns. The firm lowered their target price to $32 from $43.
OTHER DOWNGRADES:
Tags: Acme Packet, AcmePacket, APKT, AstraZeneca, AZN, downgrades, Gardasil, inthenews, Marshall Ilsley, MarshallIlsley, Merck, Merck co, MerckCo, MI, MRK, On2, On2 Tech, On2 Technologies, On2Tech, On2Technologies, ONT, ZION, ZIons Bancorp, ZionsBancorp
Tax Reform in This Election Year: It's Not Likely
Which Credit Card Rewards Does the IRS Care About?
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
